What is the role of medications in the treatment of erythromelalgia?

Updated: Nov 04, 2020
  • Author: Antoine N Saliba, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

For primary erythromelalgia, the best therapy is unknown. A wide range of agents has been studied, including the following [30] :

  • Vascular agents - Aspirin, prostaglandins
  • Sodium channel blockers - Lidocaine, mexiletine, carbamazepine, oxcarbazepine
  • Calcium channel blockers - Amlodipine, nifedipine, diltiazem, high-dose oral magnesium [31]  
  • Antidepressants - Tricyclic antidepressants, serotonin reuptake inhibitors
  • Anticonvulsants - Gabapentin, pregabalin
  • Antihistamines
  • Immunosuppressants

Case reports of treatment with propranolol, epinephrine, biofeedback, sodium nitroprusside, gabapentin, and typhoid vaccine appear in the literature, as well as case series with intravenous bupivacaine, and lidocaine plus mexiletine. [32]  

Medications that affect voltage-gated sodium channels (eg, lidocaine and its oral form, mexiletine) show promise. In hereditary erythromelalgia, however, sensitivity to lidocaine may be determined by the patient's specific SCN9A genotype. [33, 34, 35, 30]

Prostacyclin may provide some benefit [36]  In a pilot study of 12 patients, iloprost (a synthetic prostacyclin analogue) improved symptoms. [36]  A double-blind, crossover, placebo-compared study of the prostaglandin E1 analog misoprostol in 21 patients with erythromelalgia found that it reduces symptoms and microvascular arteriovenous shunting. [37]  

Topical therapy has been studied, including transdermal lidocaine. [38]  A study in 12 patients reported benefit with the alpha1-agonist midodrine, 0.2%, compounded in a moisturizing skin cream and applied topically three times a day during symptoms. [39]  Poterucha et al treated 36 patients with compounded topical amitriptyline-ketamine; 75% of those patients reported a reduction in pain. [40]

A Mayo Clinic study in 31 patients found that response to treatment with corticosteroids was more likely to occur in patients who reported a precipitant for their erythromelalgia (eg, surgery, trauma, or infection) and in those who had a subacute temporal profile to disease zenith (< 21 days). In addition, patients who responded to steroids started treatment sooner—at 3 (3-12) versus 24 (17-45) months (P = 0.003). [41]

In cases that are associated with other disorders, treating the original disease might improve symptoms. One case report described a patient with seronegative polyarthritis who developed erythromelalgia and was successfully treated with intravenous immunoglobulins. [42]

For erythromelalgia related to thrombocytosis, aspirin is usually the treatment of choice. Other nonsteroidal anti-inflammatory drugs (NSAIDs) provide relief of short duration. Anagrelide may be an alternative. Other platelet-inhibiting agents (eg, ticlopidine and dipyridamole) have no effect.

Monitor for complications, response to treatment, and development of a myeloproliferative disorder because erythromelalgia often precedes the clinical appearance of polycythemia vera or essential thrombocythemia.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!